Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on DBV Technologies SA – American (DBVT – Research Report) and keeping the price target at $19.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sam Slutsky has given his Buy rating due to a combination of factors that highlight the promising future of DBV Technologies SA – American. One of the primary reasons is the upcoming pivotal data from the Phase 3 VITESSE trial for Viaskin Peanut, which is expected to be released in the fourth quarter of this year. If the trial results are positive, the product could be launched as early as the second half of 2026, offering a safer and more convenient treatment option for young children with peanut allergies compared to existing therapies like OIT and Xolair.
Moreover, there is strong enthusiasm from both physicians and patients for Viaskin Peanut, which is anticipated to significantly expand the market for treating peanut allergies in children. Additionally, the potential approval of Viaskin Peanut for younger children aged 1-3 by 2027 further strengthens the company’s growth prospects. The expected availability of omalizumab biosimilars in 2026 is seen as less impactful for DBV’s target demographic, suggesting that Viaskin Peanut will remain a competitive option. Overall, these factors contribute to a positive outlook for DBV Technologies, justifying the Buy rating.
In another report released on June 26, Citizens JMP also reiterated a Buy rating on the stock with a $21.00 price target.